Indications
Talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy.
Composition
- Active substance
- talquetamab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Talvey
- Active substance
- talquetamab
- ATC code
- L01FX29
- Therapeutic area
- Multiple Myeloma
- Marketing authorisation holder
- Janssen-Cilag International N.V.